Effect of chagasic sera on the rat isolated atrial preparation: immunological, morphological and function aspects.
An antibody reacting with the plasma membrane of working myocardial cells, skeletal muscle fibres, and endothelial cells (EVI antibody) has been described in the sera of patients with Chagas' disease. In the present study of rat isolated atrial preparations beating in ddifferent media, direct immunofluorescence and ultrastructural immunohistochemical procedures indicate that the antibody can interact with the living tissue, becoming fixed to the plasma membranes. Transmission electronmicroscopy studies also showed the presence of sarcolemmal alterations. These observations suggest a possible pathogenic effect of the EVI antibody. The presence of EVI-positive sera in the beating medium leads to a significant increase in the frequency of contractions; no significant effects of EVI-positive sera in contractile force were seen. The increase in frequency could be prevented by previous treatment with a b-adrenergic blocking agent (MJ-1999), but not by an x-blocker (phentolamine) or by an anti-histamine compound (cyproheptadine). The changes described were observed only in those atrial preparations which were beating in media containing EVI-positive sera. In those atria beating in control media (KR,KR plus normal human serum, KR plus EVI-negative chagasic serum), neither immunological nor morphological or functional changes wersence of EVI-positive chagasic serum diminished atrial stimulation after added norepinephrine. These results suggest the possibility that the EVI antibody may act as a b-adrenergic agonist at the cell plasma membrane level. Such an effect might account for some of the clinical features of chronic Chagas' heart disease.
D000818:Animals; D001666:Binding Sites, Antibody; D014355:Chagas Disease / Q000276:immunology*; D003533:Cyproheptadine / Q000494:pharmacology; D005455:Fluorescent Antibody Technique; D006325:Heart Atria / Q000187:drug effects / Q000276:immunology / Q000503:physiopathology / Q000648:ultrastructure; D006801:Humans; D007106:Immune Sera / Q000494:pharmacology*; D008297:Male; D008854:Microscopy, Electron; D009200:Myocardial Contraction / Q000187:drug effects; D009206:Myocardium / Q000276:immunology*; D009638:Norepinephrine / Q000494:pharmacology; D010646:Phentolamine / Q000494:pharmacology; D051381:Rats; D013015:Sotalol / Q000494:pharmacology
D007106:Immune Sera; D003533:Cyproheptadine; D013015:Sotalol; D009638:Norepinephrine; D010646:Phentolamine